Mark is an industry veteran having spent the last 20 years with a number of leading MNC’s and locals layers in both China and abroad.
Mark has spent the last 14 years in China first building the commercial operations for AZ followed by setting a venture backed pharmaceutical company – NovaMed. NovaMed was sold to a US listed company SCLN in 2011 with Mark staying on until late 2012 to lead the China operations.
Mark has recently established a new venture backed company – Nuance Biotech, led by a globally experienced team with a strong track in China and abroad. The company is focussed on targeting development , regulatory and commercial stage assets.